DBV Technologies

DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood.

Filings

179 filings

All Inside information114 Threshold crossing51 Earnings release10 Universal registration document2 Half-year financial report2

23/01/2026
Franchissement de seuils
Threshold crossingFrench
23/01/2026
Franchissement de seuils et déclaration d'intention
Threshold crossingFrench
23/01/2026
Franchissement de seuils
Threshold crossingFrench
23/01/2026
Franchissement de seuils
Threshold crossingFrench
23/01/2026
Franchissements de seuils et déclaration d'intention
Threshold crossingFrench
20/01/2026
Franchissement de seuils et déclaration d'intention
Threshold crossingFrench
20/01/2026
Franchissement de seuils et déclaration d'intention
Threshold crossingFrench
20/01/2026
Franchissement de seuils
Threshold crossingFrench
20/01/2026
Franchissements de seuils
Threshold crossingFrench
19/01/2026
Franchissement de seuils
Threshold crossingFrench
19/01/2026
Franchissement de seuils
Threshold crossingFrench
19/01/2026
Franchissement de seuils et déclaration d'intention
Threshold crossingFrench
19/01/2026
Franchissements de seuils
Threshold crossingFrench
19/01/2026
Franchissement de seuils
Threshold crossingFrench
17/01/2026
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing
Inside informationFR
12/01/2026
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 décembre 2025
Inside informationFrench
07/01/2026
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
Inside informationFR
05/01/2026
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
Inside information
16/12/2025
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
Inside informationFR
02/12/2025
Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2025
Inside informationFrench
17/11/2025
Franchissements de seuils
Threshold crossingFrench
13/11/2025
Franchissement de seuils
Threshold crossingFrench
13/11/2025
Franchissement de seuils
Threshold crossingFrench
12/11/2025
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
Inside informationFR
04/11/2025
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Inside informationFR
03/11/2025
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
Inside information
03/11/2025
DBV Technologies annonce la nomination de Kevin Trapp, dirigeant chevronné du secteur, au poste de Directeur Commercial
Inside informationFrench
03/11/2025
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025
Inside information
03/11/2025
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 octobre 2025
Inside informationFrench
30/10/2025
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
Inside informationFR
30/10/2025
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting
Inside informationFR
29/10/2025
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
Inside informationFR
28/10/2025
DBV Technologies Reports Third Quarter 2025 Financial Results
Inside informationFR
20/10/2025
Franchissement de seuils
Threshold crossingFrench
14/10/2025
Franchissement de seuils
Threshold crossingFrench
06/10/2025
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
Inside informationFR
18/09/2025
DBV Technologies Announces Resignation of Board Member
Inside informationFR
05/09/2025
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq
Inside informationFR
03/09/2025
DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Inside informationFR
01/08/2025
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025
Inside informationFR
29/07/2025
DBV Technologies announces filing of 2025 Half-Year Report ? Conditions for accessing or consulting the Report
Inside informationFR
29/07/2025
DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results
Earnings releaseFR
29/07/2025
Rapport financier semestriel
Half-year financial reportFrench
28/07/2025
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
Inside informationFR
22/07/2025
DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer
Inside informationFR
25/06/2025
DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old
Inside information
20/06/2025
Franchissement de seuils
Threshold crossingFrench
17/06/2025
Franchissement de seuils
Threshold crossingFrench
12/06/2025
DBV Technologies to Participate in Upcoming EAACI Congress 2025
Inside informationFR
11/06/2025
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting
Inside informationFR
04/06/2025
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 30, 2025
Inside informationFR
03/06/2025
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document
Inside informationFR
15/05/2025
Combined General Meeting of June 11, 2025
Inside informationFR
06/05/2025
Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2025
Inside informationFR
05/05/2025
DBV Technologies to Participate in the Citizens JMP Life Sciences Conference
Inside informationFR

About

ISIN: FR0010417345
Ticker: DBV
LEI: 969500PVBQFWQKVDMD80
Sector: Health care
Founded: 2002
Country of registration: FR
Last filing: 30/07/2026, 23:40

Wikipedia

Description from Wikidata, CC0 licence.

Filing history

Filings per month

Sept 23May 24Jan 25Sept 25Aug 26

Document types

Across the whole archive